Pulse Biosciences, Inc. (PLSE) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Instruments & Supplies secteur d'activité. Le siège social de l'entreprise est situé à Miami, CA, United States. Le PDG actuel est Paul Arthur LaViolette.
PLSE a date d'introduction en bourse 2016-05-18, 75 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $1.37B.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
